Aclarion, Inc.ACON
Price (close)
$2.59
Market cap
$6.4M
P/E
—
Revenue (TTM)
$83,769
Net income
-$9.2M
Dividend yield
—
1-year total return
-67.7%
Net margin
-10978.5%
Revenue growth
33.1%
Debt / equity
—
What Aclarion, Inc. does.
leverages Magnetic Resonance Spectroscopy (“MRS”), and proprietary biomarkers to optimize clinical treatments. Aclarion’s
technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association)
article is now the most costly healthcare condition in the United States. The Company is currently utilizing Artificial Intelligence (“AI”)
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $60,292 | $60,444 | $75,404 | $45,724 | $75,730 |
| Net income | — | -$5.0M | -$7.1M | -$4.9M | -$7.0M | -$7.2M |
| Free cash flow | — | — | — | -$3.6M | -$5.3M | -$7.2M |
More on ACON.
- Aclarion, Inc. summary
- Aclarion, Inc. financial statements
- Aclarion, Inc. key metrics
- Aclarion, Inc. health scores and style box
- Aclarion, Inc. earnings
- Aclarion, Inc. dividends
- Aclarion, Inc. valuation
- Aclarion, Inc. ownership and insiders
- Aclarion, Inc. peers
Figures from Aclarion, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.